The major goal of this work was to develop CEA-targeted NPs of PLGA and PEG as a novel platform to deliver 5-FU to CRC cells, thus increasing 5-FU bioavailability and providing a tumor cell-specific anti-cancer activity. This evidence concerns the gene CEACAM5 and colorectal carcinoma.